Phillips, Lawrence D., Fasolo, Barbara, Zafiropoulos, Nikolaos and Beyer, Andrea (2011) Is quantitative benefit–risk modelling of drugs desirable or possible? Drug discovery today: technologies, 8 (1). e3-e10. ISSN 1740-6749
Preliminary research results with drug regulators in several European Agencies show that quantitative models developed with groups of assessors and specialists can integrate scientific data with expert value judgements, thereby extending the capabilities of regulators, and stimulating new insights about key trade-offs. As a result, the rationale for the benefit-risk balance becomes more transparent, communicable and consistent.
|Additional Information:||© 2011 Elsevier|
|Library of Congress subject classification:||R Medicine > RS Pharmacy and materia medica|
|Sets:||Research centres and groups > Management Science Group
Departments > Management
Actions (login required)
|Record administration - authorised staff only|